http://jco.ascopubs.org/content/31/26/3197.short?rss=1 a comparison of the dose dense AC-paclitaxel regimen versus the TAC regimen was equivalent, and there was no benefit from adding in gemcitabine. Reassuring, as local oncologists inc myself have drifted /run away from using TAC due to its toxicity. Maybe, we might have hoped indeed that dose-dense (full dose sequential ) may have been better than TAC with its subadditive doses of doxorubicin and docetaxel.
